688506 Stock Overview
Engages in the research and development, production, and marketing of small molecule chemical, macromolecular biological, and antibody-drug conjugate drugs in China and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sichuan Biokin Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥145.73 |
52 Week High | CN¥215.71 |
52 Week Low | CN¥76.32 |
Beta | 0 |
11 Month Change | -19.03% |
3 Month Change | -22.98% |
1 Year Change | 48.10% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 354.70% |
Recent News & Updates
Shareholder Returns
688506 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -12.5% | -1.2% | 1.1% |
1Y | 48.1% | -18.9% | -20.4% |
Return vs Industry: 688506 exceeded the CN Pharmaceuticals industry which returned -18.9% over the past year.
Return vs Market: 688506 exceeded the CN Market which returned -20.4% over the past year.
Price Volatility
688506 volatility | |
---|---|
688506 Average Weekly Movement | 6.1% |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 5.4% |
10% most volatile stocks in CN Market | 8.5% |
10% least volatile stocks in CN Market | 3.6% |
Stable Share Price: 688506's share price has been volatile over the past 3 months.
Volatility Over Time: 688506's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 2,264 | Yi Zhu | www.baili-pharm.com |
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and marketing of small molecule chemical, macromolecular biological, and antibody-drug conjugate drugs in China and internationally. Sichuan Biokin Pharmaceutical Co.,Ltd.
Sichuan Biokin Pharmaceutical Co.,Ltd. Fundamentals Summary
688506 fundamental statistics | |
---|---|
Market cap | CN¥61.93b |
Earnings (TTM) | CN¥4.21b |
Revenue (TTM) | CN¥5.80b |
13.9x
P/E Ratio10.1x
P/S RatioIs 688506 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688506 income statement (TTM) | |
---|---|
Revenue | CN¥5.80b |
Cost of Revenue | CN¥244.46m |
Gross Profit | CN¥5.56b |
Other Expenses | CN¥1.34b |
Earnings | CN¥4.21b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 10.51 |
Gross Margin | 95.79% |
Net Profit Margin | 72.61% |
Debt/Equity Ratio | 23.0% |
How did 688506 perform over the long term?
See historical performance and comparison